NCT07145151View on ClinicalTrials.gov

A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

PHASE2RecruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

August 22, 2025

Primary Completion Date

June 4, 2027

Study Completion Date

August 31, 2027

Conditions
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions
DRUG

UBT251

UBT251 administered subcutaneously (SC) once a week.

DRUG

Placebo

Placebo,SC,once a week for 48 weeks

Trial Locations (1)

100044

RECRUITING

Beijing Tsinghua ChangGung Hospital, Beijing

All Listed Sponsors
lead

The United Bio-Technology (Hengqin) Co., Ltd.

INDUSTRY